Evaluation of efficacy and safety using Acellular Dermal Matrix as a Substitute for Middle Hepatic Vein Reconstruction During Living Donor Liver Transplantation, single-center, single-arm, prospective pilot study

Chungnam National University Hospital0 个研究点目标入组 10 人开始时间: 待定最近更新: 2023年3月6日

适应症

试验速览

暂无简介。

•1) Adults over 19 ~ 70 years old undergoing live liver transplant surgery using the right lobe of the modified liver
•2) GWRW > 0.8, MELE Score < 20, Selected Patients from the Patient Group

•1) Patients with living liver transplantation using the left lobe of the liver
•2) Patients with living liver transplant using extended right lobe (when MHV reconstruction is not required)
•3) If the right lobe starch section of the liver is dominant and the flow of the reconstructed middle vein is blocked, the patient's
•If it is expected to have a prognosis
•4) Those who cannot perform both liver CT or liver Doppler tests
•5) Those who are judged unsuitable to participate in this clinical trial by other researchers

发起方